tbuckley/cabot-search huggingface dataset:
Pediatric sibling donor bone marrow transplant: Assessing distress in donors and family members
Authors: P. S. Hinds, W. Pelletier, M. A. Alderfer, S. Davies, R. D. Pentz
Journal: Journal of Clinical Oncology (2009)

e20625 Background: When a child is diagnosed with cancer, the entire family is affected. In qualitative studies, 28–81% of siblings of children with cancer display behavioral maladjustment. Quantitative studies show similar findings, documenting up to a three-fold increase in clinically significant behavioral problems among siblings of children with cancer. Methods: In order to better understand sibling distress we conducted 3–4 interviews using grounded theory methodology (a qualitative strategy to explore common themes and develop theory) with each family member over 9 years old of 7 families with a child undergoing a sibling donor bone marrow transplant for cancer or sickle cell anemia. Participants also completed standardized scales related to coping. Results: Of the 29 subjects interviewed, 6 were African American, 4 Hispanic and 19 white. Six parents had at least a college degree and income was evenly distributed from $5,000 to &gt;$80,000 a year. Children, including 4 patients, 6 donor siblings and 5 other siblings, ranged in age from 9 to 18. Based on the grounded theory analysis of each interview, we theorize that siblings experience less distress if the parents share the patient care giving. Our data support this hypothesis, with analysis of interviews indicating improved coping in families that shared care giving for the transplant recipient, and increased distress in families in which all the patient care giving was performed by the mother, a commonly used strategy. Conclusion: In order to potentially facilitate increased family functioning and decrease caregiver burden, parents should be encouraged to share care giving when feasible. Our study shows that systematic interviews can explore the family experience of pediatric transplantation and allow development of improved support systems for families of children undergoing sibling donor bone marrow transplantation. No significant financial relationships to disclose.
Association of single-nucleotide polymorphisms of USP7 gene with breast cancer suscepbility in Chinese women.
Authors: Huangang Jiang, Fuxiang Zhou, You Wang, Yuehua Wei, Hui Xu, Liu Hu, Wenbo Wang, Hong Zhao
Journal: Journal of Clinical Oncology (2014)

27 Background: The tumor suppressor p53 pathway plays a crucial role in preventing carcinogenesis. It was reported that activity of p53 was regulated by USP7 (Ubiquitin Specific Peptidase 7) and TSPYL5 (Testis-specific Y-encoded-like protein 5). This study was carried out to assess the association between single nucleotide polymorphisms (SNPs) in P53, USP7, TSPYL5 genes and the breast cancer susceptibility in Chinese Han women. Methods: DNA was extracted from the peripheral blood samples of breast cancer patients and age-matched controls. In the first stage, tag SNPs of P53, USP7, and TSPYL5 genes were selected with Hapmap database and Haploview program. The matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay was used for genotyping. Then, two positive SNPs were determined by polymerase chain reaction- restricted fragment length polymorphisms assay (PCR-RFLP) in the second stage. The ethics committee of Zhongnan Hospital of Wuhan University authorized this study. Results: In the first stage, 23 SNPs were selected and detected in 192 cases and 192 controls. The results demonstrated that the distribution of genotype of rs12924995, rs2304467 in USP7 gene was different in cases and controls (p = 0.026, 0.037, respectively). In the second stage, these two SNPs were determined. A total of 975 cases and 910 controls enrolled in the present study. Hardy-Weinberg equilibrium of rs2304467 and rs12924995 in the control group was tested (p = 0.979, 0.111). Multivariate analysis showed that breast cancer risk of women with C allele (CC or CG genotype) increased (p &lt; 0.001, odds ratio = 1.87, 95% confidence interval, 1.44-2.44), compared with rs2304467 GG carriers. Besides, women with rs12924995A allele (AA or AC genotype) had higher risk of breast cancer than those with CC genotype (P=0.002, odds ratio=1.36, 95% confidence interval, 1.21-1.65). Breast cancer risk of women carried rs2304467C allele and rs12924995A allele also increased (p &lt; 0.001, odds ratio = 2.05, 95% confidence interval, 1.54-2.73). Conclusions: SNPs rs2304467 and rs12924995 in USP7 gene are associated with breast cancer susceptibility in Chinese Han women.
Incidence of Age-Related Macular Degeneration in a Multi-Ethnic United States Population
Authors: Diana E. Fisher, Barbara E.K. Klein, Tien Y. Wong, Jerome I. Rotter, Xiaohui Li, Sandi Shrager, Gregory L. Burke, Ronald Klein, Mary Frances Cotch
Journal: Ophthalmology (2016)

To describe the incidence of age-related macular degeneration (AMD) and associated risk factors in 4 racial/ethnic groups (white, black, Hispanic, and Chinese) residing in the United States.Prospective cohort study.A total of 3811 participants, aged 46 to 86 years, from the Multi-Ethnic Study of Atherosclerosis (MESA) cohort, with retinal data collected twice, on average, 8 years apart.Fundus images, taken using a digital camera through dark-adapted pupils using a standard protocol and the same equipment at both study visits, were graded centrally for early and late AMD on the basis of drusen size, type and area, increased retinal pigment, retinal pigment epithelial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System. Demographic, clinical, and laboratory measures were included in multivariable regression models to determine their impact on the variation in AMD incidence among racial/ethnic groups.Incident early and late AMD.The overall 8-year age- and sex-standardized incidence of early and late AMD were 4.1% and 2.3%, respectively, with incidence of early and late AMD highest in whites (5.3% and 4.1%, respectively), intermediate in Chinese (4.5% and 2.2%, respectively) and Hispanics (3.3% and 0.8%, respectively), and lowest in blacks (1.6% and 0.4%, respectively). By adjusting for age and sex, blacks had a 70% lower risk of developing early AMD than whites, and this decreased only slightly to a 67% lower risk after multivariable adjustment. By adjusting for age, sex, and race/ethnicity, hyperopia was associated with early AMD (odds ratio [OR], 1.51; 95% confidence interval [CI], 1.04-2.20), as was astigmatism (OR, 1.47; 95% CI, 1.00-2.16), but not myopia (P = 0.29). Age, race/ethnicity, current smoking, hyperopia, and AMD-susceptibility genotypes Complement Factor H (CFH) RS1061170 and Age Related Maculopathy Susceptibility 2 (ARMS2) RS3793917 were independently associated with incident early AMD in multivariable models for the combined sample. However, the only statistically significant factor consistently associated with incident early AMD across the 4 racial/ethnic groups was increasing age. Risk factors for late AMD were not assessed because of its low incidence, particularly across racial/ethnic groups.Variation in the incidence of early AMD exists among racial/ethnic groups in the United States and is not explained by the clinical, genetic, and environmental factors included in this study.
Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure
Authors: Steven J. Keteyian, Mahesh Patel, William E. Kraus, Clinton A. Brawner, Timothy R. McConnell, Ileana L. Piña, Eric S. Leifer, Jerome L. Fleg, Gordon Blackburn, Gregg C. Fonarow, Paul J. Chase, Lucy Piner, Marianne Vest, Christopher M. O’Connor, Jonathan K. Ehrman, Mary N. Walsh, Gregory Ewald, Dan Bensimhon, Stuart D. Russell
Journal: Journal of the American College of Cardiology (2016)
Tumor stem cell vaccine for NSCLC and GBM-assessment of feasibility, adverse events and efficacy
Authors: G. A. Moviglia, G. Varela, C. A. Gaetta, M. Guerra, A. Carrizo, H. Costanzo, P. Farina, F. Bastos, M. T. Moviglia-Brandolino, A. Paes de Lima, S. Merino
Journal: Journal of Clinical Oncology (2006)

2556 Background: Only a small part of the total cell population of a malignancy has the potential to grow and regenerate the total tumor mass. The rest are only differentiated forms of those stem cells. This biologic characteristic seems to be responsible for the failure to achieve long term remission for several peptide based vaccines. Method: To overcome this obstacle, we have established a technique that uses tumor stem cells (TSC) to develop a TSC-B cell vaccine. To test efficacy and best administration form of this vaccine, we have proceeded as follow: First: Pieces from total or partial resections of GBM or NSCLC were mechanically dissociated to a single cell suspension. Cells were cultured in an appropriate tissue culture medium and allowed to grow for two weeks or until they reach a semi confluent stage. Then, cells were harvested and re-seeded. This procedure was repeated 6 to 24 weeks according to vitality and growth characteristics of cells. Finally, Tumor cells were fused with autologous B cells. The hybrid was kept in culture and used for an intra lymph node immunization every 3 weeks. To potentiate its action, 3 days prior to its administration we co-incubated the hybrid with either autologous dendritic cells or autologous mononuclear cells. Adverse events were evaluated by the “Common terminology criteria for Adverse Events (AE), 2004” developed by NIH. Definitions are available on the web at http://ctep.cancer.gov/reporting/ctc.html . Clinical efficacy of this procedure was evaluated according RESIST criteria for NSCLC and a combination of MRI and spectroscopy for GBM. Results: At present 8 patients with GBM with post surgical second relapse and who had received complete radiotherapy doses were treated. We have also treated 6 patients with NSCLC:4 with minimal residual disease and 2 with measurable residual disease. Patients have presented minor adverse events, mainly referred to inflammation of the injection site. The median survival rates registered to the present are 22 months for GBM patients and 3 years for patients with stage IV NSCLC who had minimal residual disease at the beginning of the treatment. Conclusion: A tumor stem cell vaccine seems to be a feasible and effective therapy with very low toxicity for the treatment of advanced GBM and NSCLC patients. No significant financial relationships to disclose.
Erythropoetin (epoetin beta) once weekly in anemic patients with advanced cancer of the stomach or gastroesophageal junction: Interim results of a randomized German AIO phase II trail
Authors: M. H. Moehler, M. Geissler, J. Raedle, M. Ebert, H. Scherubl, D. Flieger, T. Seufferlein, P. Galle, S. Kanzler
Journal: Journal of Clinical Oncology (2007)

15133 Background: Tumor-related or chemotherapy-induced anemia is common in gastrointestinal cancer patients and results in reduced quality of life and worse prognosis. Thus, the effectiveness of erythropoetin (epoetin beta) treatment (EB) to achieve and maintain a target haemoglobin (Hb) level of ≥ 11 g/dl was assessed within a randomised German AIO phase II study to assess efficacy of irinotecan/capecitabine versus cisplatin/capecitabine in advanced gastric or lower esophageal cancer. Methods: Patients (pts) with untreated locally advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction (KPS ≥ 60%, &gt; one measurable lesion, adequate organ functions) were randomized to receive 3-weekly cycles of either irinotecan 250 mg/m 2 d1 (arm A) or cisplatin 80 mg/m 2 d1 (arm B). Capecitabine was administered at 2000 mg/m 2 for 14 days in both arms. In both arms, EB (30,000 I.E. once weekly) was given at Hb of &lt; 11 g/dl and continued until Hb ≥ 12 g/dl. If after 4 treatment weeks, Hb increase was &lt; 0.5 g/dl, EB was increased to 30,000 I.E. twice weekly. FACT-An questionnaires were completed at each cycle. Results: At time of abstract submission, 81 pts were randomized to A (37 pts) or B (44 pts). 23 pts received at least 3 EB injections (A: 10 pts, B: 13 pts). Median Hb prior to EB was 10.5 g/dl (A: 10.4 g/dl, B: 10.5 g/dl) and median Hb at end of EB was 11.6 g/dl (A: 11.5 g/dl, B: 11.75 g/dl). During EB, 80 % of A and 77 % of B achieved target Hb of ≥ 11 g/dl with a median rise in Hb of 2.0 g/dl (A: 1.4 g/dl, B: 2 g/dl). 5 pts in A and 7 pts in B responded with a ≥ 1 g/dl rise in Hb during first 4 weeks. FACT-An questionnaires showed no change from baseline to end of EB. Among evaluable pts with EB (20 pts) versus without EB (34 pts), response (CR + PR) and tumor control rates (CR + PR + SD) were 60% vs 35% and 85% vs 70%, respectively. Conclusions: EB is effective in raising Hb levels in advanced or metastatic gastric cancer. Patients receiving EB tend to show a better response to chemotherapy. No significant financial relationships to disclose.
Postchemotherapy consolidative surgery for metastatic urothelial carcinoma.
Authors: Cesar Emilio Ercole, Steven C. Campbell, Robert Dreicer, Jorge A. Garcia, Michael C. Gong, Venkatesh Krishnamurthi, Andrew J. Stephenson
Journal: Journal of Clinical Oncology (2015)

362 Background: The role of post-chemotherapy consolidative surgery for metastatic urothelial carcinoma (UC) is controversial and supported by small, single-center series in select patients. We sought to assess our experience with post-chemo retroperitoneal lymph node (RPLN) dissection for primary metastatic or relapsed UC to the retroperitoneum (with or without concomitant cystectomy and/or nephroureterectomy). Methods: Since 2008, 15 patients with metastatic or relapsed UC of the bladder or upper tracts (UT) and associated RPLN metastases were considered for post-chemo consolidative surgery. Records were reviewed for response to therapy, final pathology, and impact of surgery on overall survival (OS). Chemo agents used were provider dependent with 9 patients treated with gemcitabine/cisplatin, 3 with gem/carboplatin, and 2 with methotrexate, vinblastine, doxorubicin, cisplatin (1 received a combination due to intolerance). A median of 3.5 cycles were given in the adjuvant (n=5) and induction (n=10) setting. Seven patients presented with UT disease, of those 3 with relapse; median follow-up was 31.6 months (mos, IQR 14, 72), with 1 patient deceased. Nine patients had a bladder primary, 5 had induction chemo (median follow-up: 22 mos, IQR 16, 40), with 1 alive, 4 dead of disease, and 2 of other causes. To date, 13 patients have undergone surgery. Overall median follow-up is 23 mos. Results: Five patients (3 bladder, 2 UT) were noted to have radiographic complete response (CR) with induction and a median survival of 21.5 mos, with one patient alive at 7 years. All but one patient in the UT group are alive. Two patients had pathological CR, both were in the bladder cohort and died at 8 and 23 mos post-op. For all other patients, final pathology noted a median of 2 LN positive for malignancy (average 3.6). Neither chemo nor timing of administration showed a difference in OS. Conclusions: There is a role for post-chemo consolidative surgery in selected patients with metastatic UC. Compared to patients with the primary tumor in the UT, those with a primary bladder tumor and RPLN fared worse with a shorter overall survival time. More studies are necessary to better define the role of surgery in this setting.
Distribution of Virus Particles and Mammary Tumor Virus Antigens in Mouse Mammary Tumors, Transformed BALB/c Mouse Kidney Cells, and GR Ascites Leukemia Cells2
Authors: Jero Calafat, Femke Buijs, Philomena C. Haqernan, J. Links, J. Hilgers, Annemarie Hekman
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Distribution of Virus Particles and Mammary Tumor Virus Antigens in Mouse Mammary Tumors, Transformed BALB/c Mouse Kidney Cells, and GR Ascites Leukemia Cells Get access Jero Calafat, Jero Calafat 3Department of Electron Microscopy, The Netherlands Cancer Institute, Sarphatistraat 108, Amsterdam, The Netherlands. Search for other works by this author on: Oxford Academic PubMed Google Scholar Femke Buijs, Femke Buijs 4Department of Biology, The Netherlands Cancer Institute. Search for other works by this author on: Oxford Academic PubMed Google Scholar Philomena C. Haqernan, Philomena C. Haqernan 4Department of Biology, The Netherlands Cancer Institute. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Links, J. Links 4Department of Biology, The Netherlands Cancer Institute. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Hilgers, J. Hilgers 4Department of Biology, The Netherlands Cancer Institute. Search for other works by this author on: Oxford Academic PubMed Google Scholar Annemarie Hekman Annemarie Hekman 5Department of Immunology, The Netherlands Cancer Institute. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 53, Issue 4, October 1974, Pages 977–991, https://doi.org/10.1093/jnci/53.4.977 Published: 01 October 1974 Article history Received: 24 December 1973 Revision received: 13 May 1974 Accepted: 17 June 1974 Published: 01 October 1974
Abstract 13685: Toll-Like Receptor 2 Mediates Cardiac Adaptive Response to Pressure Overload
Authors: Yasutomi Higashikuni, Ryozo Nagai, Masataka Sata
Journal: Circulation (2012)

Background: Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate immune system. TLR2 is a member of the TLR family, and has been shown to recognize not only foreign substances, but also endogenous ligands, which induce inflammatory response called homeostatic inflammation. Recently, homeostatic inflammation has been revealed to contribute to the pathophysiology of various diseases. However, the role of homeostatic inflammation mediated by TLR2 on pressure overload-induced cardiac hypertrophy remains unclear. Methods and Results: Pressure overload was induced in 8- to 12-week-old wild-type (WT) and TLR2 knock-out (KO) mice by transverse aortic constriction (TAC). In WT mice, TLR2 mRNA expression at 2 weeks after TAC was up-regulated compared with that after sham operation (1.32±0.18 versus 0.50±0.03, n=4, p=0.004). At 2 weeks after TAC, KO mice showed reduced cardiac hypertrophy and fibrosis with more left ventricular dilatation and impaired systolic function compared with ...
Serum proteomic profiling of advanced gastric cancer and identification of proteomic changes following response to epirubicin, cisplatin and capecitabine chemotherapy as diagnostic and predictive biomarkers
Authors: H. H. Helgason, J. Y. Engwegen, A. Cats, H. Boot, M. Kuiper, M. Zapatka, M. Joerger, J. H. Beijnen, J. H. Schellens
Journal: Journal of Clinical Oncology (2007)

4537 Background: Gastric cancer is the fourth most commonly diagnosed cancer and is the second leading cause of cancer death worldwide. Prognosis is highly dependent on stage at diagnosis making early diagnosis mandatory. By using SELDI - TOF mass spectrometry we compared serum protein profiles of gastric cancer patients with healthy controls and those of gastric cancer patients responding to first-line ECC chemotherapy with those with no response or early progressive disease. Methods: Serum from patients with advanced gastric cancer (GC) was obtained, according to a predefined schedule, prior to start of first-line epirubicin (50 mg/m 2 day 1), cisplatin (60 mg/m 2 day 1) and capecitabine (1,000 mg/m 2 d1–14) chemotherapy (ECC) and serially before each treatment cycle every 3 weeks and analyzed by standardized SELDI-TOF MS/MS. Serum proteomic profiles of GC patients were compared with those of matched healthy controls and proteomic profile changes in responding and non-responding patients were analyzed. Results: In total 82 patients (mean age 57 years) were treated with mean 5 ECC cycles resulting in a response rate of 35%, mean time to progression of 7.1 months and mean overall survival of 12.4 months (95% CI: 10.7 - 14.1). By comparing GC patients and healthy controls we identified 18 m/z values that significantly (p &lt; 0.00001) differentiated between the two groups (m/z 2.7 - 66.6 kDa). Comparison of responding and non-responding patients identified 2 proteins, m/z 3109 and 7559 Da, potentially predicting response (p &lt; 0.001). Serial analysis of proteins changing differently during chemotherapy according to response will be performed. Conclusions: We identified 18 m/z values/proteins that highly (p &lt; 1.0 E-05) discriminated between gastric cancer patients and healthy controls serving as candidate biomarkers of gastric cancer and 2 m/z values that significantly predicted response to chemotherapy. No significant financial relationships to disclose.
Tumor-Associated Specificity of Serum-Mediated Inhibition of Lymphocyte Stimulation by Autochthonous Human Tumors2
Authors: Farkas Vánky, Jan Stjernswärd, George Klein, Ladislau Steiner, Lars Lindberg
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Tumor-Associated Specificity of Serum-Mediated Inhibition of Lymphocyte Stimulation by Autochthonous Human Tumors Get access Farkas Vánky, Farkas Vánky Department of Tumor Biology, Karolinska Institute; Radiumhemmet, Clinic of Neurosurgery, Karolinska Sjukhuset, Stockholm; and Department of Orthopedic Surgery, University Hospital of Lund, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar Jan Stjernswärd, Jan Stjernswärd Department of Tumor Biology, Karolinska Institute; Radiumhemmet, Clinic of Neurosurgery, Karolinska Sjukhuset, Stockholm; and Department of Orthopedic Surgery, University Hospital of Lund, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar George Klein, George Klein Department of Tumor Biology, Karolinska Institute; Radiumhemmet, Clinic of Neurosurgery, Karolinska Sjukhuset, Stockholm; and Department of Orthopedic Surgery, University Hospital of Lund, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar Ladislau Steiner, Ladislau Steiner Department of Tumor Biology, Karolinska Institute; Radiumhemmet, Clinic of Neurosurgery, Karolinska Sjukhuset, Stockholm; and Department of Orthopedic Surgery, University Hospital of Lund, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar Lars Lindberg Lars Lindberg Department of Tumor Biology, Karolinska Institute; Radiumhemmet, Clinic of Neurosurgery, Karolinska Sjukhuset, Stockholm; and Department of Orthopedic Surgery, University Hospital of Lund, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 1, July 1973, Pages 25–32, https://doi.org/10.1093/jnci/51.1.25 Published: 01 July 1973 Article history Received: 31 January 1973 Accepted: 27 February 1973 Published: 01 July 1973